Having qualified as a pharmacist in 2013 and having an interest in pharmaceutical formulation development and oncology, I began a PhD focusing on the development of a novel skin cancer treatment. An ever-increasing search is in progress for novel active pharmaceutical ingredients’s and the effective formulation of them. I recognise we must go beyond the simple identification of useful actives that provide the basis for novel claims and benefits. As formulation scientists we must determine the active compounds’ absorption, body distribution, metabolism and excretion thus formulate a suitable drug delivery system. I aim to reduce potential side effects and, in view of the high cost that can accompany new materials, incorporate these compounds into targeted, controlled-release delivery systems.
My current research within AMRI concerns the development of a drug delivery system in the treatment of Preeclampsia (PE); a major cause of maternal and perinatal mortality and morbidity worldwide. The molecular mechanism underlying its pathogenesis are unclear thus no cure is available except for premature delivery of fetus and placenta. My research within this body of work includes the development of optimised neutral, cationic and anionic liposomes, a lipid based bubble system, loaded with specific PE treatment compounds. These liposomes are designed to target the placenta and reduce off site effects. This research may be important for the development of new therapeutic approaches for clinical treatment of PE.
2013 GPhC registration
Browser does not support script.